Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade)
Source: SeekingAlpha
2026-03-30 16:20:39 ET
Just over one month ago , I upgraded Corcept Therapeutics Incorporated ( CORT ) to Buy following the company's loss in its patent litigation against Teva Pharmaceuticals ( TEVA ). This was a setback for the company, allowing Teva to release a generic version of Corcept's drug Korlym and potentially calling into question the legacy Cushing's syndrome franchise that delivered $761M in 2025 sales....
Read the full article on Seeking Alpha
For further details see:
Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade)
Teva Pharmaceutical Industries Limited American Depositary Shares
NASDAQ: TEVA
TEVA Trading
-1.98% G/L:
$29.88 Last:
1,036,287 Volume:
$29.45 Open:
TEVA Latest News
March 30, 2026 08:00:00 am
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI(TM) (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
March 19, 2026 04:30:00 pm
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
TEVA Stock Data
$39,421,335,208
1,138,314,769
0.04%
264
N/A
Pharmaceuticals
Healthcare
IL
Tel Aviv
